At the 26th International AIDS Conference in Rio de Janeiro, researchers presented compelling evidence for long-acting HIV prevention and treatment options. For decades, managing HIV has depended on daily pill regimens. The latest findings demonstrate that less frequent dosing can offer strong protection and viral suppression, giving individuals choices that fit their personal routines.
The PURPOSE 1 and PURPOSE 2 trials evaluated lenacapavir, an injectable drug administered once every six months for HIV prevention, achieving exceptionally high protection and over 90 percent participant adherence. For treatment, the ISLEND trials tested a once-weekly pill combining islatravir and lenacapavir, reducing the treatment burden from 365 daily tablets to just 52 pills annually. Lenacapavir is already being introduced in African nations like Zambia and Zimbabwe.
Health experts stress that having diverse options is critical. According to UNAIDS, adolescent girls and young women in Africa account for 63 percent of new HIV infections. Researchers compare this approach to family planning, where individuals can select methods suited to different life stages.
However, turning scientific progress into public health success faces challenges, particularly after recent cuts in international funding disrupted community delivery systems. To deliver these tools equitably, governments are working to integrate HIV care into primary health services while negotiating lower prices with drug manufacturers like Gilead Sciences through voluntary licensing agreements.
Difficult words
- regimen — a prescribed plan or schedule for medical treatmentregimens
- adherence — the action of following a medical treatment or rule
- equitably — in a fair way that treats everyone equally
- integrate — to combine separate things into a single complete system
- disrupt — to stop something from continuing in a normal waydisrupted
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why might long-acting HIV prevention options be helpful for people who struggle with daily routines?
- What steps can governments take to make new medical treatments affordable and accessible to everyone?
- How does combining specialized care with primary health services impact patients and healthcare systems?
Related articles
Study links autoantibodies to long COVID symptoms
A new study reports that some people with long COVID make autoantibodies that attack brain and nerve tissue. When researchers gave these antibodies to mice, the animals developed pain, fatigue and balance problems similar to patient symptoms.
